P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease

Autor:	P Higgins, D Ginsburg, K Gilder, B Walsh, B English, S Turner, P Klassen, S Hanauer, C Barish, B Yacyshyn
Rok vydání:	2019
Předmět:	Agonist Crohn's disease medicine.drug_class business.industry Gastroenterology medicine Cannabinoid receptor type 2 Chronic abdominal pain General Medicine Pharmacology business Highly selective medicine.disease
Zdroj:	Journal of Crohn's and Colitis. 13:S318-S318
ISSN:	1876-4479 1873-9946
DOI:	10.1093/ecco-jcc/jjy222.542
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3218be61668d93fd5e87347c08c44376 https://doi.org/10.1093/ecco-jcc/jjy222.542 Zobrazit plný text záznamu